可切除边缘性胰腺癌新辅助治疗后的手术并发症：从基准到随机临床试验 - Suppr

Suppr

超能文献

Surgical Complications After Neoadjuvant Treatment for Borderline Resectable Pancreatic Cancer: From Benchmarks to Randomized Clinical Trials.

作者信息

Søreide Kjetil, Larsson Patrik, Pandanaboyana Sanjay

机构信息

Department of Gastrointestinal Surgery, Stavanger University Hospital, Stavanger, Norway.

Department of Clinical Medicine, University of Bergen, Bergen, Norway.

出版信息

Ann Surg Oncol. 2024 Dec;31(13):8481-8484. doi: 10.1245/s10434-024-16134-7. Epub 2024 Aug 31.

DOI:10.1245/s10434-024-16134-7

PMID:39215772

Abstract

摘要

相似文献

Surgical Complications After Neoadjuvant Treatment for Borderline Resectable Pancreatic Cancer: From Benchmarks to Randomized Clinical Trials.可切除边缘性胰腺癌新辅助治疗后的手术并发症：从基准到随机临床试验

Ann Surg Oncol. 2024 Dec;31(13):8481-8484. doi: 10.1245/s10434-024-16134-7. Epub 2024 Aug 31.

Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial.总新辅助 FOLFIRINOX 对比新辅助吉西他滨为基础的放化疗和辅助吉西他滨治疗可切除和交界可切除胰腺癌（PREOPANC-2 试验）：一项全国多中心随机对照试验的研究方案。

BMC Cancer. 2021 Mar 23;21(1):300. doi: 10.1186/s12885-021-08031-z.

Comparison of neoadjuvant treatment and surgery first for resectable or borderline resectable pancreatic carcinoma: A systematic review and network meta-analysis of randomized controlled trials.新辅助治疗与手术优先治疗可切除或交界可切除胰腺癌的比较：一项随机对照试验的系统评价和网络荟萃分析。

PLoS One. 2024 Mar 7;19(3):e0295983. doi: 10.1371/journal.pone.0295983. eCollection 2024.

Surgical resection rates after neoadjuvant therapy for localized pancreatic ductal adenocarcinoma: meta-analysis.局部胰腺癌新辅助治疗后的手术切除率：荟萃分析

Br J Surg. 2022 Dec 13;110(1):34-42. doi: 10.1093/bjs/znac354.

Predictive value of baseline serum carbohydrate antigen 19-9 level on treatment effect of neoadjuvant chemoradiotherapy in patients with resectable and borderline resectable pancreatic cancer in two randomized trials.在两项随机试验中，基线血清碳水化合物抗原 19-9 水平对可切除和交界可切除胰腺癌患者新辅助放化疗治疗效果的预测价值。

Br J Surg. 2023 Sep 6;110(10):1374-1380. doi: 10.1093/bjs/znad210.

Comparing upfront surgery with neoadjuvant treatments in patients with resectable, borderline resectable or locally advanced pancreatic cancer: a systematic review and network meta-analysis of randomized clinical trials.比较可切除、边界可切除或局部进展期胰腺癌患者的 upfront 手术与新辅助治疗：随机临床试验的系统评价和网络荟萃分析。

Int J Surg. 2024 Jun 1;110(6):3900-3909. doi: 10.1097/JS9.0000000000001313.

Borderline resectable pancreatic cancer and the role of neoadjuvant chemoradiotherapy.可切除边缘性胰腺癌及新辅助放化疗的作用

Updates Surg. 2016 Sep;68(3):235-239. doi: 10.1007/s13304-016-0392-x. Epub 2016 Sep 15.

Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomised controlled trials.可切除和交界可切除胰腺癌的新辅助治疗或 upfront 手术：随机对照试验的荟萃分析。

Eur J Cancer. 2022 Jan;160:140-149. doi: 10.1016/j.ejca.2021.10.023. Epub 2021 Nov 24.

Prognostic value of neoadjuvant therapy for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomized controlled trials.新辅助治疗可切除和交界可切除胰腺癌的预后价值：一项随机对照试验的荟萃分析。

PLoS One. 2023 Sep 6;18(9):e0290888. doi: 10.1371/journal.pone.0290888. eCollection 2023.

Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocarcinoma Treatment in Japan.可切除和交界可切除胰腺导管腺癌的新辅助和辅助治疗：日本胰腺导管腺癌治疗的现状。

Gut Liver. 2023 Sep 15;17(5):698-710. doi: 10.5009/gnl220311. Epub 2023 Feb 27.

本文引用的文献

Total Venous Control and Vein-to-the-Right Superior Mesenteric Artery Approach in Robotic Pancreatoduodenectomy.机器人胰十二指肠切除术的全静脉控制和静脉至右肠系膜上动脉入路。

Ann Surg Oncol. 2024 Dec;31(13):8721-8722. doi: 10.1245/s10434-024-16146-3. Epub 2024 Sep 16.

Postoperative Adverse Events Following Neoadjuvant Therapy and Surgery for Borderline Resectable Pancreatic Cancer in a Phase 2 Clinical Trial (Alliance A021501).在一项 2 期临床试验（Alliance A021501）中，新辅助治疗和手术治疗边界可切除胰腺癌的术后不良事件。

Ann Surg Oncol. 2024 Oct;31(10):7033-7042. doi: 10.1245/s10434-024-15670-6. Epub 2024 Jul 15.

Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial.新辅助FOLFIRINOX方案与直接手术治疗可切除胰头癌的比较（NORPACT-1）：一项多中心、随机、2期试验

Lancet Gastroenterol Hepatol. 2024 Mar;9(3):205-217. doi: 10.1016/S2468-1253(23)00405-3. Epub 2024 Jan 15.

Consensus recommendations on how to assess the quality of surgical interventions.关于如何评估手术干预质量的共识建议。

Nat Med. 2023 Apr;29(4):811-822. doi: 10.1038/s41591-023-02237-3. Epub 2023 Apr 17.

Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial.在可切除边缘的胰腺癌患者中，即刻手术与短程新辅助吉西他滨联合卡培他滨、FOLFIRINOX或放化疗的比较（ESPAC5）：一项四臂、多中心、随机、2期试验

Lancet Gastroenterol Hepatol. 2023 Feb;8(2):157-168. doi: 10.1016/S2468-1253(22)00348-X. Epub 2022 Dec 12.

Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas: The A021501 Phase 2 Randomized Clinical Trial.术前 mFOLFIRINOX 对比 mFOLFIRINOX 联合短程放疗治疗边界可切除胰腺腺癌的疗效：A021501 期随机临床试验。

JAMA Oncol. 2022 Sep 1;8(9):1263-1270. doi: 10.1001/jamaoncol.2022.2319.

Consensus Statement on Mandatory Measurements for Pancreatic Cancer Trials for Patients With Resectable or Borderline Resectable Disease (COMM-PACT-RB): A Systematic Review and Delphi Consensus Statement.可切除或边缘可切除疾病患者胰腺癌临床试验强制性测量共识声明 (COMM-PACT-RB)：系统评价和德尔菲共识声明。

JAMA Oncol. 2022 Jun 1;8(6):929-937. doi: 10.1001/jamaoncol.2022.0168.

Results of a Phase II Study on the Use of Neoadjuvant Chemotherapy (FOLFIRINOX or GEM/nab-PTX) for Borderline-resectable Pancreatic Cancer (NUPAT-01).NUPAT-01 期研究：新辅助化疗（FOLFIRINOX 或 GEM/nab-PTX）治疗边界可切除胰腺癌的结果。

Ann Surg. 2022 Jun 1;275(6):1043-1049. doi: 10.1097/SLA.0000000000005430. Epub 2022 Mar 3.

Eur J Cancer. 2022 Jan;160:140-149. doi: 10.1016/j.ejca.2021.10.023. Epub 2021 Nov 24.

The effect of preoperative chemotherapy and chemoradiotherapy on pancreatic fistula and other surgical complications after pancreatic resection: a systematic review and meta-analysis of comparative studies.术前化疗和放化疗对胰腺切除术后胰瘘和其他手术并发症的影响：系统评价和比较研究的荟萃分析。

HPB (Oxford). 2021 Sep;23(9):1321-1331. doi: 10.1016/j.hpb.2021.04.027. Epub 2021 May 19.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验